A $250M target fund pairing milestone-driven therapeutics with operating businesses, manufacturing and commercialization capabilities to translate science into clinic — designed to reduce downside risk.
Available to accredited investors only. Access to the deck and data room is granted after an application and executed non-disclosure agreement.
Breakthrough biology frequently stalls for want of manufacturing, patient access, evidence and operating infrastructure. Aether invests across the continuum that turns science into real-world impact.
A continuum from science to a healthier, longer tomorrow. Value depends on execution, evidence and market conditions.
A single fund commitment provides blended exposure across selective therapeutic innovation and a group of revenue-generating service and operating businesses, unified by a fund-wide AI strategy.
Milestone-driven equity in high-impact, longevity-focused cell and gene therapies. Value depends on scientific, regulatory, CMC and controlled-evidence milestones.
Manufacturing and supply chain, patient access and evidence, and operating acquisitions — earnings and platform value that can support portfolio execution and hedge innovation risk.
Innovation capital is staged to defined, verifiable evidence gates — fund, prove, and advance or stop at each milestone.
Acquisition strategy is underwritten to operating earnings and transaction discipline, not multiple expansion alone.
A general-partner group combining biotech, clinical, operating and healthcare transaction experience, with scientific advisers.
Vertical integration across patients, manufacturing and therapeutic innovation is designed to capture excess returns while the operating businesses hedge the downside risk of innovation.
Excess returns captured by integrating patients, manufacturing and therapeutic innovation in one ecosystem.
Revenue-generating service businesses are intended to hedge downside risk from innovation.
Synergistic acquisitions create capital-recycling opportunities across the fund's lifetime.
A fund-wide and asset-focused AI strategy is applied to drive efficacy across the portfolio.
Rapid capital deployment into pre-diligenced assets rather than cold sourcing.
Important information. This website is confidential discussion material intended solely for accredited investors and is not an offer to sell or a solicitation of an offer to buy any security. Any offering will be made only through definitive offering documents and in accordance with applicable securities exemptions.
Interests are restricted and illiquid. The Fund may not reach its target size, complete transactions, make distributions or achieve any modeled outcome, and investors may lose all invested capital. Statements about portfolio companies, targets, valuations, timelines and strategy are forward-looking and may prove wrong; they are not performance, promises or guarantees. Recipients should conduct independent legal, tax, accounting, scientific and investment diligence. Nothing here replaces professional advice or formal offering documentation.